실적분석 2026년 8월 26일

Mesoblast ($MESO) FY2026 Q4 Earnings Analysis — Ryoncil Revenue Misses at $36M; Full-Year Guidance Maintained

Earnings Scorecard

Revenue: Ryoncil Q4 net revenue of $36 million (FY2026 Q4; the prior-year quarter is effectively meaningless given the early launch period), consensus was $47.13 million ❌ Miss

EPS: Not yet finalized — the audited income statement has not been released, so no confirmed EPS is available

Guidance: Not provided — the company has not publicly disclosed official FY2027 revenue or earnings outlook

Stock reaction: After-hours +0.00% ($16.84) — as of 05:10 KST on 08-27

The Positives

$115 million in first-year revenue: Ryoncil's net revenue for the first year of commercialization (FY2026) landed within the company's target range.

$103 million in cash: Cash on hand as of the end of June, remaining after fully retiring maturing debt.

Adult-indication trial launched: Enrollment has begun for the adult graft-versus-host disease (GvHD) registry trial, which addresses a market roughly three times the size.

Mesoblast is the company behind the first FDA-approved mesenchymal stromal cell therapy. The core story from this print is that, within the first year following approval, the product has secured prescriptions at major pediatric transplant centers. At the same time, follow-on indications such as neuromuscular disease and chronic low back pain have advanced into the clinical stage, opening additional paths to broaden the revenue base.

The Negatives

Q4 revenue fell short of expectations: At $36 million, it came in well below the $47.13 million the market was looking for.

Earnings figures missing: Audited net loss and EPS have not been released as of this point.

Continued cash burn: FY2026 net cash used in operating activities totaled $43.8 million.

The fact that revenue has started to flow and the fact that the company is on a path to profitability are two different stories. Given that the first-half net loss reached $40.2 million, the key question for this audited report was how much the back-half loss had narrowed — and that number is still not in hand. The additional point worth noting is that $50 million was used to repay debt.

What Management Said

The company expressed satisfaction with the expansion of Ryoncil prescriptions among pediatric GvHD patients and stated that, building on its first-year revenue base, it intends to deploy capital prudently to reach milestones such as additional approvals. Management placed greater emphasis on the adult-indication expansion timeline than on the fact that it met its revenue target, and the market is focused on the next approval timeline rather than this quarter's numbers.

Market Reaction and What to Watch Next

The stock barely moved in after-hours trading despite the Q4 revenue shortfall because the figure had already been disclosed in late July via the quarterly activity report, leaving nothing new for the market to digest.

How much the audited FY2026 net loss and EPS narrowed versus the first half

Progress on the adult GvHD registry trial's rollout across 40 US sites

Timing of the 12-month primary endpoint readout from the chronic low back pain Phase 3 trial